NasdaqCM - Nasdaq Real Time Price USD

BioXcel Therapeutics, Inc. (BTAI)

2.6300 +0.0200 (+0.77%)
At close: April 26 at 4:00 PM EDT
2.6400 +0.01 (+0.38%)
After hours: April 26 at 7:34 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,380.0000
1,380.0000
375.0000
--
--
Cost of Revenue
1,260.0000
1,260.0000
20.0000
--
--
Gross Profit
120.0000
120.0000
355.0000
--
--
Operating Expense
167,739.0000
167,739.0000
160,000.0000
106,936.0000
82,297.0000
Operating Income
-167,619.0000
-167,619.0000
-159,645.0000
-106,936.0000
-82,297.0000
Net Non Operating Interest Income Expense
-7,665.0000
-7,665.0000
-5,685.0000
4.0000
128.0000
Other Income Expense
-3,769.0000
-3,769.0000
-427.0000
--
155.0000
Pretax Income
-179,053.0000
-179,053.0000
-165,757.0000
-106,932.0000
-82,169.0000
Net Income Common Stockholders
-179,053.0000
-179,053.0000
-165,757.0000
-106,931.0000
-82,169.0000
Diluted NI Available to Com Stockholders
-179,053.0000
-179,053.0000
-165,757.0000
-106,931.0000
-82,169.0000
Basic EPS
-7.36
-6.15
-5.92
-4.05
-3.79
Diluted EPS
-7.36
-6.15
-5.92
-4.05
-3.79
Basic Average Shares
28,786.7500
29,129.0000
28,015.0000
26,373.0000
21,683.0000
Diluted Average Shares
28,786.7500
29,129.0000
28,015.0000
26,373.0000
21,683.0000
Total Operating Income as Reported
-171,782.0000
-171,782.0000
-159,645.0000
-106,935.0000
-82,297.0000
Total Expenses
168,999.0000
168,999.0000
160,020.0000
106,936.0000
82,297.0000
Net Income from Continuing & Discontinued Operation
-179,053.0000
-179,053.0000
-165,757.0000
-106,931.0000
-82,169.0000
Normalized Income
-174,890.0000
-174,890.0000
-165,757.0000
-106,931.0000
-82,169.0000
Interest Income
5,649.0000
5,649.0000
2,528.0000
44.0000
155.0000
Interest Expense
13,314.0000
13,314.0000
8,213.0000
40.0000
27.0000
Net Interest Income
-7,665.0000
-7,665.0000
-5,685.0000
4.0000
128.0000
EBIT
-165,739.0000
-165,739.0000
-157,544.0000
-106,892.0000
-82,142.0000
EBITDA
-165,421.0000
-165,421.0000
-157,217.0000
-106,595.0000
-81,954.0000
Reconciled Cost of Revenue
1,260.0000
1,260.0000
20.0000
--
--
Reconciled Depreciation
318.0000
318.0000
327.0000
297.0000
188.0000
Net Income from Continuing Operation Net Minority Interest
-179,053.0000
-179,053.0000
-165,757.0000
-106,931.0000
-82,169.0000
Total Unusual Items Excluding Goodwill
-4,163.0000
-4,163.0000
--
--
155.0000
Total Unusual Items
-4,163.0000
-4,163.0000
--
--
155.0000
Normalized EBITDA
-161,258.0000
-161,258.0000
-157,217.0000
-106,595.0000
-81,954.0000
12/31/2020 - 3/8/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AXSM Axsome Therapeutics, Inc.
71.71
+0.27%
 
FGEN FibroGen, Inc.
1.0400
+1.96%
 
VTYX Ventyx Biosciences, Inc.
3.9300
-3.20%
 
ALLO Allogene Therapeutics, Inc.
2.8900
+1.23%
 
GTHX G1 Therapeutics, Inc.
3.9900
+3.37%
 
VINC Vincerx Pharma, Inc.
0.7300
-18.59%
 
BPTH Bio-Path Holdings, Inc.
2.6800
+1.71%
 
AMLX Amylyx Pharmaceuticals, Inc.
1.7600
-1.12%
 
ANVS Annovis Bio, Inc.
18.01
+32.43%
 
ANTX AN2 Therapeutics, Inc.
2.3200
+1.75%